Takeda expected to report higher quarterly revenue ahead of October 29 results
Earnings Preview, citing LSEG data, says two analysts expect Takeda's revenue to rise 5.6% to JPY1.175 trillion before its October 29 report.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
Takeda Pharmaceutical is scheduled to report results on October 29 for the quarter ended September 30, 2026. The mean forecast of two analysts compiled by LSEG points to revenue of JPY1.175 trillion, up 5.6% from JPY1.11 trillion a year earlier.
The average earnings estimate stands at JPY134.54 per share, unchanged over the past three months. Ratings are mostly positive: three analysts rate the stock buy or strong buy, with no holds, sells or strong sells.
The median 12-month price target from Wall Street analysts is $21.90, about 7.2% above the last close of $20.43. The information comes from Earnings Preview.
why it matters
The event is moderately important: results from a large drugmaker can influence Japan's pharma sector and the TAK American depositary receipts. The forecasts rest on a small sample of two analysts, so reported figures could differ noticeably.
market impact
Takeda and Japanese pharma: results versus forecasts set sentiment for TAK shares
tags
instruments
sources
- Takeda Pharmaceutical Company Limited expected to post earnings of JPY134.54 a share — Earnings Preview, 27 October 2026 at 06:16 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗